Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I

Neuromuscular Disorders

Volumn 23, Issue 2, 2013, Pages 112-115

  Finkel, Richard S ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; CHOP INTEND; Compound motor action potential; Spinal muscular atrophy type 1; Werdnig Hoffmann disease

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN 1;

APGAR SCORE; ARTICLE; CASE REPORT; CHOP INTEND MOTOR SCALE; CLINICAL EXAMINATION; COMPOUND MOTOR ACTION POTENTIAL; DEATH; EARLY INTERVENTION; FAMILY HISTORY; GENE DELETION; GENETIC ANALYSIS; HUMAN; INFANT; LUNG INFECTION; MALE; MOTONEURON; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NERVE CELL NECROSIS; NERVE STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEWBORN; NORMAL VALUE; PALLIATIVE THERAPY; PRIORITY JOURNAL; RATING SCALE; SMN1 GENE; SPINAL MUSCULAR ATROPHY; SPINAL MUSCULAR ATROPHY TYPE 1;

ACTION POTENTIALS; ELECTROPHYSIOLOGICAL PHENOMENA; FATAL OUTCOME; HUMANS; INFANT, NEWBORN; MALE; MOTOR ACTIVITY; PALLIATIVE CARE; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 84873204839     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.09.006     Document Type: Article

References (16)

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978, 15:409-413.
2. Zerres K., Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995, 52:518-523.
3. Lefebvre S., Burglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
4. Lefebvre S., Burlet P., Liu Q., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16:265-269.
5. Fidzianska A., Rafalowska J., Glinka Z. Ultrastructural study of motoneurons in Werdnig-Hoffmann disease. Clin Neuropathol 1984, 3:260-265.
6. Lunn M.R., Wang C.H. Spinal muscular atrophy. Lancet 2008, 371:2120-2133.
7. Thomas N.H., Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 1994, 4:497-502.
8. Oskoui M., Levy G., Garland C.J., et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007, 69:1931-1936.
9. Swoboda K.J., Prior T.W., Scott C.B., et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005, 57:704-712.
10. Lewelt A., Krosschell K.J., Scott C., et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010, 42:703-708.
11. Le T.T., McGovern V.L., Alwine I.E., et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet 2011, 20:3578-3591.
12. Kariya S., Park G.H., Maeno-Hikichi Y., et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008, 17:2552-2569.
13. Glanzman A.M., Mazzone E., Main M., et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010, 20:155-161.
14. Glanzman A.M., McDermott M.P., Montes J., et al. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther 2011, 23:322-326.
15. Prior T.W., Snyder P.J., Rink B.D., et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010, 152A:1608-1616.
16. Dobrowolski S.F., Pham H.T., Pouch-Downes F., Prior T.W., Naylor E.W., Swoboda K.J. Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling. Clin Chem 2012, 58:1033-1039.